Innovative ophthalmic technology

Article

Incorporating the LAL into your practice

It is often said that a chain is only as strong as its weakest link. A similar sentiment applies to the way in which a clinical practice adopts a new tool. Innovative ophthalmic technologies hold much promise, however, this promise is soon lost if such technologies are not implemented in a manner that compliments existing patient care standards.

The postoperative journey

The adjustment and lock-in process can take several weeks and involves a maximum of four visits to the treating physician's clinic. If this is considered alongside the requirement for all patients to wear UVblocking sunglasses at all times, it is clear that any patient who opts for this IOL must be accepting of a more time-intensive postoperative care plan. Similarly, physicians must adjust their standard approach to IOL implantation to accommodate this unique care plan.

Education is paramount

First and foremost, time must be taken to thoroughly explain the process to potential patients. Patients who opt for the LAL inevitably invest a lot of time, faith and money into the lens procedure. As a result, they need to have a full understanding of the concept that underlies the lens and its results. In my experience, patients do not have a great deal of knowledge about the existing range of solutions for cataracts and refractive error, as such, thorough patient education is essential.

In my practice, we have optical engineers and opticians who are dedicated to educating patients about different lens options. This is something that I am also involved in, but to ensure that all patients seeking IOL implantation are completely informed about all possible solutions, I find that delegating this task allows patient education to be performed with maximum efficiency. Once a patient has narrowed down his or her options, I then discuss these options with them in detail.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.